Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
종목 코드 HOTH
회사 이름Hoth Therapeutics Inc
상장일Feb 15, 2019
CEOKnie (Robb)
직원 수2
유형Ordinary Share
회계 연도 종료Feb 15
주소1177 Avenue Of The Americas
도시NEW YORK
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호10036
전화16467562997
웹사이트https://hoththerapeutics.com/
종목 코드 HOTH
상장일Feb 15, 2019
CEOKnie (Robb)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음